ReviewParasitology2025
Towards elimination of genital schistosomiasis in Africa: Outlining strategic public health objectives and measures to protect future generations.
Review in Parasitology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Urogenital schistosomiasis has 2 gender-specific manifestations, male genital schistosomiasis (MGS) and female genital schistosomiasis (FGS). The burdens of MGS and FGS are multifaceted, encompassing financial hardship, emotional and mental health problems and sometimes social stigmatization. Given the pernicious nature of sequelae in the genitalia, managing these chronic health conditions is expensive, difficult and problematic in resource poor settings. Key challenges include lack of epidemiological data on the burden of MGS and FGS, inadequate knowledge among primary and auxiliary health care workers, leading to misdiagnosis, incorrect treatment administration, e.g. overuse of antibiotics, and a lack of appropriate point-of-care diagnostic equipment. Prevention of MGS and FGS is therefore more preferable, however, current preventive programmes and chemotherapy campaigns offering praziquantel are becoming more resource constrained and in most endemic areas are not reaching at-risk adults (and adolescents), sufficiently. Furthermore, there are limited prospects for adequate access to treatment in pre-school children where infections can be first acquired. Therefore, we propose 3 key recommendations guiding movement towards elimination of schistosomiasis as a public health problem: scaling-up praziquantel treatment for other at-risk groups; developing a targeted One Health approach to reduce environmental transmission in both humans and animals; Multi-stakeholder collaboration and community engagement for effective implementation of Water Sanitation and Hygiene components of disease control. Whilst maintaining a school-based approach is still foundational, targeted and sustainable expansion of preventive chemotherapy to other at-risk groups within communities is needed to secure real prospects in elimination of genital schistosomiasis as a public health problem in Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.